Treatment News : Monkeys Achieve Drug-Free Control of SIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 9, 2013

Monkeys Achieve Drug-Free Control of SIV

Adding both an arthritis drug and a chemotherapy drug to a highly intensified antiretroviral regimen appears to have led to a drug-free control of HIV among macaque monkeys. Publishing their findings in the journal Retrovirology, a group of Italian and American researchers added the gold salt auranofin and the chemosensitizing agent buthionine sulfoximine (BSO) to a five-drug antiretroviral regimen given to macaques infected with simian immunodeficiency virus (SIV). In a previous study, the researchers had found that the addition of auranofin succeeded in reducing both the viral reservoir and the post-therapy viral load set point.

Of the seven monkeys in the trial, all received the five-drug ARV cocktail. Two of them also received auranofin, three of them received auranofin and BSO, and two received no additional therapies.

After the researchers stopped the therapy of the three monkeys taking auranofin and BSO, their viral loads initially rebounded. But with time the animals experienced a significant drop of viral RNA and DNA in peripheral blood cells—an indicator of a diminished viral reservoir—as compared with levels seen before the monkeys began ARV treatment. The monkeys ultimately achieved enough control of their infections to prevent the development of AIDS. The researchers found that the presence of CD8 cells as well as an enhanced level of cellular immune response among the monkeys played a key role in this apparently successful therapy.

The researchers wrote, “The level of post-therapy viral set point reduction achieved in this study is the largest reported so far in chronically SIVmac251-infected macaques and may represent a promising strategy to improve over the current ‘ART [antiretroviral treatment] for life’ plight.”

The investigators plan to start a human clinical trial of this therapy in early 2014.

To read the study, click here.

Search: HIV, macaque monkeys, Retrovirology, auranofin, buthionine sulfoximine, BSO, simian immunodeficiency virus, SIV, viral control.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.